RxDoctor Payments Data

Joshua Roe, MD

Cornea and External Diseases Specialist · Tacoma, WANPI 1083988851

Payments from drug & device makers

$972in general payments, 2019–2025

Across 25 payments — averaging $38.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$321
  • Biotissue Holdings Inc.$170
  • Dompe US, Inc.$136
  • Glaukos Corporation$111
  • Sun Pharmaceutical Industries Inc.$47
  • Tarsus Pharmaceuticals, Inc.$44
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$279,112
Medicare patients
603
Services billed
2,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj21$838,984
LumiganBimatoprost131$96,648
RestasisCyclosporine56$79,954
RocklatanNetarsudil Mesylat/Latanoprost42$37,096
ValacyclovirValacyclovir Hcl289$29,996
XiidraLifitegrast19$29,071
CombiganBrimonidine Tartrate/Timolol22$22,655
Prednisolone Acetate339$21,395
RhopressaNetarsudil Mesylate30$19,882
Loteprednol Etabonate88$14,357
TyrvayaVarenicline Tartrate12$14,127
MieboPerfluorohexyloctane/Pf11$11,146
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol47$6,977
Alphagan PBrimonidine Tartrate12$6,338
SimbrinzaBrinzolamide/Brimonidine Tart16$5,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$136$838,98421 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$19$40,21730 claims
AlconSimbrinza$321$5,99416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Tacoma

Where these figures come from

Is this you, or does something look wrong? →